A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

NCT02564198 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Pediatric Solid Tumor
Refractory Tumor
Recurrent Tumor
CNS Malignancies

Interventions

DRUG: Ramucirumab

Sponsor

Eli Lilly and Company

Collaborators

[object Object]